Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma

This study has been completed.
Sponsor:
Information provided by:
Activaero GmbH
ClinicalTrials.gov Identifier:
NCT01200108
First received: September 10, 2010
Last updated: November 14, 2011
Last verified: November 2011

September 10, 2010
November 14, 2011
March 2010
October 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01200108 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma
A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma Requiring Chronic Oral Corticosteroid Treatment

The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral corticosteroid dose and stability/improvement of clinical parameters related to asthma in the targeted subject population. Ultimately, the goal is to free subjects with severe asthma from the burden of chronic oral steroid therapy.

Not Provided
Interventional
Phase 2
Not Provided
Asthma
Drug: Budesonide
  • Experimental: Budesonide high dose via AKITA (1mg/2ml)
    Intervention: Drug: Budesonide
  • Experimental: Budesonide low dose via AKITA (0.5mg/2ml)
    Intervention: Drug: Budesonide
  • Active Comparator: Budesonide high dose via conventional nebulizer (1mg/2ml)
    Intervention: Drug: Budesonide
  • No Intervention: Placebo via AKITA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
November 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent prior to the performance of any study-related procedures
  • Age ≥ 18 and ≤ 65 year of age Diagnosis of asthma (ATS definition, either allergic or non-allergic) for ≥ 6 months
  • Asthma treated for at least 3 months with inhaled (ICS) and oral corticosteroids (OCS). Exact baseline level will be measured during the screening period by subject diary entries
  • FEV1 ≥ 40% or ≤ 79% predicted at the Screening or Baseline Visit
  • Documented increase of FEV1 within 15-30 minutes after the use of inhaled Salbutamol at the Screening Visit or within 2 years prior to Screening
  • Mandatory usage of long-acting β-agonists
  • A negative pregnancy test must be available for any women of childbearing potential at screening and, in addition, a negative urine pregnancy test must be present at randomization (prior to randomization to one of the treatment groups!)
  • Women of childbearing potential must agree to use a reliable method of contraception from the screening until 4 weeks after study completion or after study drug discontinuation in case study drug treatment is stopped prematurely. - In this study, hormone-based contraceptives alone are not considered as reliable method

Exclusion Criteria:

  • History of allergy or adverse experience with Budesonide
  • Pregnant women or nursing mothers
  • Upper respiratory tract infection within 4 weeks of Screening
  • Emergency room visit for treatment of asthma exacerbation within 4 weeks of Screening
  • Hospitalization for asthma within 3 months of Screening
  • Use of anti-IgE, methotrexate, oral gold, Dapsone, or i.v. gamma globulin within 3 months of Screening
  • Treatment with other investigational asthma treatment within 30 days prior to Screening
  • Evidence of chronic lung diseases other than asthma, including but not limited to: cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA), COPD, chronic bronchitis and emphysema
  • History of medication noncompliance
  • History of significant medical illness or condition that in the Investigator's opinion places the subject at undue risk by participating in the study
  • Past episode of anaphylaxis with severe respiratory symptoms
  • Oral corticosteroid average daily dose exceeding a maximum amount
  • Currently smoking or history of smoking ≥ 10 pack years
  • Taking oral or i.v. corticosteroids for any disease indication other than asthma
  • Abnormal lab values for chemistry tests at Screening that may indicate impaired ability to metabolize and/or excrete Budesonide (AST, ALT > 3 times upper limit of normal range, serum creatinine > 1.5 times upper limit of normal range)
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Poland,   Ukraine
 
NCT01200108
Acti-AICS-001
Yes
Dr. Thomas Hofmann, Activaero GmbH
Activaero GmbH
Not Provided
Principal Investigator: Peter Kardos, MD Peter Kardos
Activaero GmbH
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP